Total number of specimens = 2100 | Previous anti-TB treatment status | ||||||
---|---|---|---|---|---|---|---|
New | Previously treated | Total | |||||
N | % (95% CI) | N | % (95% CI) | N | % (95% CI) | ||
Total DST results | 121 | 5.8 | 98 | 4.7 | 219 | 10.4 | |
I | Any resistance to H | 32 | 26.4 (19.4–35.4) | 46 | 46.9 (37.1–56.8) | 78 | 35.6 (29.3–42.0) |
Any resistance to R | 12 | 9.9 (5.8–16.5) | 27 | 27.6 (18.7–36.4) | 39 | 17.8 (12.7–22.9) | |
Any resistance to E | 18 | 14.9 (9.6–22.3) | 33 | 33.7 (24.3–43.0) | 51 | 23.3 (17.7–28.9) | |
Any resistance to S | 34 | 28.1 (20.9–36.7) | 34 | 34.7 (25.3–44.1) | 68 | 31.1 (24.9–37.2) | |
II | Resistance to H only | 10 | 8.3 (4.7–15.3) | 14 | 14.3 (7.1–20.9) | 24 | 10.9 (6.8–15.1) |
Resistance to R only | 0 | 0 (0–0) | 0 | 0 (0–0) | 0 | 0 (0–0) | |
Resistance to E only | 0 | 0 (0–0) | 7 | 7.1 (1.9–12.1) | 7 | 3.1 (0.9–5.5) | |
Resistance to S only | 15 | 12.4 (8.6–21.4) | 11 | 11.2 (4.8–17.2) | 26 | 11.9 (7.6–16.2) | |
Total mono-resistance | 25 | 20.7 (13.4–27.9) | 32 | 32.6 (23.4–41.9) | 57 | 26.02 (20.2-31.9) | |
III | H + R | 1 | 0.8 (−0.8–2.8) | 6 | 6.1 (1.3–10.7) | 7 | 3.1 (0.9–5.5) |
H + R + E | 3 | 2.5 (0.04–6.04) | 7 | 7.1 (1.9–12.1) | 10 | 4.5 (1.8–7.3) | |
H + R + S | 3 | 2.5 (0.04–6.04) | 5 | 5.1 (0.7–9.3) | 8 | 3.7 (1.2–6.2) | |
H + R + E + S | 5 | 4.1 (1.1–8.9) | 9 | 9.2 (3.3–14.7) | 14 | 6.4 (3.2–9.6) | |
Total MDR | 12 | 9.9 (4.6–15.2) | 27 | 27.6 (18.7–36.4) | 39 | 17.8 (12.7–22.9) | |
IV | H + E | 4 | 3.3 (0.5–7.5) | 3 | 3.1 (−0.4–6.4) | 7 | 3.1 (0.9–5.5) |
H + S | 5 | 4.1 (1.1–8.9) | 2 | 2.04 (−0.8–4.8) | 7 | 3.1 (0.9–5.5) | |
H + E + S | 1 | 0.8 (0.8–2.8) | 3 | 3.1 (−0.4–6.4) | 4 | 1.8 (0.1–3.6) | |
R + E | 0 | 0 (0–0) | 0 | 0 (0–0) | 0 | 0 (0–0) | |
R + S | 0 | 0 (0–0) | 0 | 0 (0–0) | 0 | 0 (0–0) | |
R + E + S | 0 | 0 (0–0) | 0 | 0 (0–0) | 0 | 0 (0–0) | |
E + S | 5 | 4.1 (1.1–8.9) | 4 | 4.1 (0.12–7.9) | 9 | 4.1 (1.5–6.7) | |
Total poly-resistance other than MDR | 15 | 12.4 (6.8–18.3) | 12 | 12.2 (5.8–18.7) | 27 | 12.3 (8.0–16.7) |